Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 15/20 | 0.42 |
| ▸ | CDK2 | P24941 | 15/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 15/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214743 | 0.88 | CCNA2 (0.37) | CCNA2CDK2CCNA1IGF1R | |
| SCHEMBL2735393 | 0.87 | CCNA2 (0.54) | CCNA2CDK2CCNA1GAAIGF1R | |
| SCHEMBL214000 | 0.76 | CCNA2 (0.61) | CCNA2CDK2CCNA1RET | |
| SCHEMBL214405 | 0.68 | — | — | |
| SCHEMBL214661 | 0.68 | GAA (0.49) | GAA | |
| SCHEMBL214879 | 0.68 | MAPT (0.34) | GAARET | |
| SCHEMBL214742 | 0.67 | CDK2 (0.52) | CCNA2CDK2CCNA1RET | |
| SCHEMBL14222316 | 0.67 | GAA (0.54) | GAA | |
| SCHEMBL215229 | 0.67 | MAPT (0.63) | GAA | |
| SCHEMBL213976 | 0.67 | MAPT (0.71) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | CCNA2 776/4885CDK2 67/4885CCNA1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.